SEC Tracker
Get the app

Attovia Therapeutics ATTO

Attovia Therapeutics announces positive Phase 1b results for ATTO-1310

Attovia Therapeutics (ATTO) filed an 8-K with the SEC on Nov 9, 2026, 4:10 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results, Item 8.01 Other events

Form
8-K
Filed
Importance
Major
  1. ATTO-1310 showed 82% PP-NRS4 response at Week 12 vs. 22% with placebo
  2. Single dose led to 95% suppression of IL-31 through Week 12
  3. Phase 2 trials planned for 2027 with 300+ patients in chronic pruritus
  4. Low immunogenicity with 7.8% anti-drug antibodies detected

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Attovia Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.